- Home
- RWAY vs FDMT Comparison
RWAY vs FDMT Comparison
Compare RWAY & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RWAY
- FDMT
- Stock Information
- Founded
- RWAY 2015
- FDMT 2013
- Country
- RWAY United States
- FDMT United States
- Employees
- RWAY N/A
- FDMT N/A
- Industry
- RWAY
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- RWAY
- FDMT Health Care
- Exchange
- RWAY Nasdaq
- FDMT Nasdaq
- Market Cap
- RWAY 390.5M
- FDMT 420.7M
- IPO Year
- RWAY 2021
- FDMT 2020
- Fundamental
- Price
- RWAY $10.31
- FDMT $7.99
- Analyst Decision
- RWAY Buy
- FDMT Strong Buy
- Analyst Count
- RWAY 9
- FDMT 9
- Target Price
- RWAY $11.68
- FDMT $46.75
- AVG Volume (30 Days)
- RWAY 340.5K
- FDMT 769.3K
- Earning Date
- RWAY 11-12-2024
- FDMT 11-13-2024
- Dividend Yield
- RWAY 3.88%
- FDMT N/A
- EPS Growth
- RWAY N/A
- FDMT N/A
- EPS
- RWAY 1.02
- FDMT N/A
- Revenue
- RWAY $150,078,000.00
- FDMT $17,000.00
- Revenue This Year
- RWAY N/A
- FDMT N/A
- Revenue Next Year
- RWAY N/A
- FDMT $57.85
- P/E Ratio
- RWAY $10.07
- FDMT N/A
- Revenue Growth
- RWAY N/A
- FDMT N/A
- 52 Week Low
- RWAY $9.87
- FDMT $7.32
- 52 Week High
- RWAY $13.74
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- RWAY 48.69
- FDMT 40.80
- Support Level
- RWAY $9.92
- FDMT $8.04
- Resistance Level
- RWAY $10.17
- FDMT $8.96
- Average True Range (ATR)
- RWAY 0.22
- FDMT 0.60
- MACD
- RWAY -0.01
- FDMT 0.16
- Stochastic Oscillator
- RWAY 58.27
- FDMT 36.02
About RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and Canada, with the majority of its portfolio invested in the United States.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.